pergolide
英
美
网络 培高利特; 协良行; 硫丙麦角林; 甲磺酸培高利特; 培高力特
双语例句
- The removal of pergolide products is not expected to adversely affect patient care because of the alternative therapies available.
培高利特的撤市希望对患者的治疗不会产生不利的影响，因为有其它的治疗药物可选择。 - "Based on important new drug safety information, FDA has been working with the manufacturers of pergolide products to voluntarily remove these drugs from the market," said Douglas Throckmorton, M.
基于重要的新药安全信息，FDA与培高利特产品的生产厂商决定将其撤市。 - Conclusions In this study, use of the dopamine agonists pergolide and cabergoline was associated with an increased risk of newly diagnosed cardiac-valve regurgitation.
结论：研究发现使用多巴胺受体激动剂培高利特和卡麦角林可增加新发生的心脏瓣膜返流的风险。 - FDA today is issuing a Public Health Advisory ( PHA) detailing the removal of pergolide products from the market.
FDA今天发布公共健康忠告，详细说明了培高利特撤市的情况。 - Objective: Treatment with ergot-derived dopamine agonists, pergolide, and cabergoline has been associated with an increased frequency of valvular heart disease in Parkinson's disease.
目的：使用麦角衍生的多巴胺激动剂，已经证实帕金森病人使用培高利特和卡麦角林可能增加瓣膜心脏病。 - Pergolide mesylate& a new dopamine receptor agonist
新多巴胺受体激动剂甲磺酸培高利特 - Objective To select the suitable antiparkinsonian drugs among levodopa-benserazide, pergolide and selegiline for patients with early-stage idiopathic Parkinson's disease by observing the effects on dopamine D_2 receptor.
目的比较左旋多巴-苄丝肼、培高利特、司来吉兰治疗帕金森病的疗效，观察其对纹状体突触后多巴胺D2受体的作用，筛选出适合治疗早期帕金森病的药物。 - Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease
长期使用多巴胺受体激动剂培高利特治疗帕金森病所致胸膜肺纤维化 - Pergolide for early Parkinson disease: a randomized, double blind, controlled trial
应用培高利特单药治疗早期帕金森病：随机、双盲、对照实验 - Conclusion This study demonstrates that pergolide, as an adjunct to levodopa, is a safe and effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.
结论协良行作为左旋多巴的联用药物，可明显改善帕金森病患者的临床症状及减少左旋多巴用量，且安全可靠。 - Effect of pergolide on striatal-neurotrophic activity of the rats
培高利特对大鼠纹状体神经营养活性的影响 - The average daily dose of pergolide in the senile and the non-senile groups was ( 0.40 ± 0.26) mg and ( 0.39 ± 0.20) mg, respectively and the total incidence of side-effects was 23.7%.
培高利特的平均日服用剂量老年组为（040±026）mg，非老年组为（039±020）mg，总副反应发生率为237%。 - RESULTS: Both pergolide and bromocriptine decreased the spontaneously firing rate of "sensitive" and "insensitive" DA cells.
结果：二个药物均能抑制敏感及不敏感的DA神经元自发放电活动。 - Primary investigation of protective effect of pergolide on parkinsonian rat
培高利特对帕金森病大鼠保护作用的初步研究 - Effects of pergolide on natural degeneration of striatal dopaminergic neuron and motor ability in patients with early Parkinson disease: a double blind, randomized, parallel and placebo control experiment
培高利特对早期帕金森病患者纹状体多巴胺能神经元自然变性率及其运动能力的影响：一项双盲、随机、平行、安慰剂对照实验 - Madopar may accelerate the apoptosis of dopaminergic neuron and then aggravate the severity, but pergolide does not affect the prognosis of Parkinson disease, so it is a more suitable selective drug for the treatment of early Parkinson disease.
美多巴可能会加速多巴胺能神经元的凋亡而使病情恶化，培高利特则不影响帕金森病的预后，更适合作为早期帕金森病治疗的选择药物。 - Conclusions Both pergolide and selegiline had milder effects on the specific uptake of()~ ( 131) I epidepride and may be more suitable for the treatment of patients with early-stage Parkinson's disease.
结论培高利特、司来吉兰对131I-epidepride摄取影响较小，可作为早期帕金森病患者的治疗药物。 - Pergolide in the Treatment of Very Old Patients with Parkinson's Disease
培高利特治疗超老年帕金森病10例 - The most significant reduction in UPDRS was seen in levodopa-benserazide-treated group, and then in pergolide and selegiline groups.
统一帕金森病量表评分减少：左旋多巴-苄丝肼治疗组最明显，培高利特组、司来吉兰组次之。 - Pergolide in treatment of high nervous activity disturbance after stroke
培高利特治疗脑卒中后高级神经活动障碍 - Objective To investigate the effects of pergolide and spiperone on dopamine ( DA) metabolism in striatum during forebrain ischemia-reperfusion injury in gerbils.
目的研究培高利特（pergolide）和螺哌隆（spiperone）对沙土鼠前脑缺血再灌注期纹状体多巴胺（DA）代谢的影响。 - AIM: To evaluate the efficacy and the safety of dopamine agonist& pergolide in treatment of higher nervous activity disturbance after stroke.
目的：评价应用多巴胺激动剂&培高利特治疗脑卒中后高级神经活动障碍的疗效和安全性。 - OBJECTIVE: Briefly reviewing the pharmacological action and clinical effect of pergolide mesylate, a DA receptor agonist.
目的：简述甲磺酸培高利特的药理活性和临床疗效。 - Objective To investigate the effect of pergolide on the striatal neurotrophic activity of the rats.
目的观察培高利特（pergolide）对大鼠纹状体神经营养活性的影响。